Lauren Dixon, MBChB, MRes, MRCS, University of Bristol, Bristol, UK, shared promising findings from theNLCA State of the Nation report 2024 on lung cancer diagnosis and treatment. More patients than ever are being diagnosed at stage 1 or 2, allowing for curative treatment options and improved survival rates. This is attributed in part to targeted lung health checks for early detection. While surgical resection rates have increased, there are concerns about lengthening treatment waiting times, impacting patient care. Despite reporting the highest one-year and median survival rates, improvements are needed to address delays in care pathways. Additionally, the proportion of patients receiving systemic anti-cancer therapy for advanced non-small cell lung cancer remains static, falling short of NICE guidance targets. Multidisciplinary efforts are essential to identify and address barriers to timely treatment and optimize patient outcomes. This interview took place at the BTOG 2024 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
